-

Wenzel Spine Announces Limited U.S. Commercial Launch and First Cases of its Expandable panaSIa™ SI Fusion System

AUSTIN, Texas--(BUSINESS WIRE)--Wenzel Spine, Inc., a medical device company pioneering minimally invasive surgical and analytic solutions for spinal disorders, today announced completion of first cases and the U.S. limited commercial launch of its novel panaSIa™ Expandable SI Fusion System. panaSIa is the first expandable sacroiliac (SI) fusion implant cleared by the FDA and represents a major breakthrough in addressing sacroiliac joint dysfunction with enhanced biomechanical stability and procedural efficiency.

Designed to be implanted using a posterior, minimally invasive technique, panaSIa provides joint fixation through controlled expansion across the ilium and sacrum, offering immediate mechanical stability while preserving surrounding tissue. The implant’s integrated graft chamber allows for post-expansion bone grafting without disengaging instrumentation, facilitating optimal fusion conditions and minimizing procedural complexity.

The first U.S. procedures are part of a limited commercial release taking place at select surgical centers ahead of full launch in Q4 2025.

“panaSIa is unlike any SI fusion device currently available,” said Aaron Calodney, MD, a nationally recognized leader in interventional pain medicine. “The implant expands to eliminate micro-motion, providing immediate stabilization. By slightly distracting the joint space, it may reduce pain by removing contact between the arthritic surfaces. It’s simple, elegant, and biomechanically sound—a truly next-generation solution for SI joint fusion.”

The panaSIa system expands Wenzel Spine’s portfolio of stand-alone expandable fusion technologies and reflects the company’s long-term commitment to minimally invasive innovation and surgeon-driven design.

“This launch is a defining milestone for Wenzel Spine,” said William Wilson, CEO of Wenzel Spine. “Our team has spent nearly two decades perfecting expandable device design, and panaSIa brings that legacy to a new clinical segment. We are proud to offer providers a differentiated, minimally invasive solution that transforms SI joint fusion with precision, control, and speed.”

About panaSIa™ SI Fusion System

The panaSIa SI Fusion System is a posteriorly placed, expandable implant that transfixes the ilium and sacrum to immobilize the SI joint and promote fusion. It is offered in two sizes allowing for anatomical customization, while its streamlined instrumentation enables true MIS placement. The integrated expansion mechanism and post-expansion graft delivery system simplify the workflow and reduce operative time.

panaSIa is available now in limited release and will be widely available in Q4 2025.

About Wenzel Spine, Inc.

Headquartered in Austin, Texas, Wenzel Spine, Inc. is a privately held medical technology company committed to advancing the standard of care for spinal disorders through minimally invasive surgical innovation and data-driven solutions. Wenzel Spine's technologies are used by leading spine and pain physicians across the country to streamline surgical procedures and improve patient outcomes.

To learn more, visit: www.wenzelspine.com

Contacts

William Wilson, Chief Executive Officer
512.469.0600
ceo@wenzelspine.com

Wenzel Spine, Inc.

Details
Headquarters: Austin, TX
CEO: William Wilson
Employees: 25-50
Organization: PRI

Release Versions

Contacts

William Wilson, Chief Executive Officer
512.469.0600
ceo@wenzelspine.com

More News From Wenzel Spine, Inc.

Wenzel Spine Receives FDA Clearance for First Expandable Sacroiliac (SI) Fusion Implant, panaSIa™

AUSTIN, Texas--(BUSINESS WIRE)--Wenzel Spine, Inc., a medical technology company focused on minimally invasive surgical and analytic solutions for spinal disorders, today announced it has received FDA clearance for its revolutionary expandable sacroiliac (SI) fusion implant, panaSIa. This milestone marks the first ever FDA clearance of an expandable SI fusion implant, offering a novel, minimally invasive solution for patients suffering from sacroiliac joint dysfunction. “We are excited to bring...

Wenzel Spine Announces Expansion of Executive Leadership Team and Planned Entry into Minimally Invasive Interventional Spine Market

AUSTIN, Texas--(BUSINESS WIRE)--Wenzel Spine, Inc., a medical technology company focused on providing minimally invasive surgical and diagnostic solutions for the treatment of spinal disorders, today is pleased to announce the expansion of its executive leadership team by appointing Charles R. Gordon as the Executive Chairman of the Board. This strategic move is poised to enhance the company's innovative edge and entry into the minimally invasive interventional spine market. William Wilson, CEO...

Wenzel Spine Receives FDA Clearance Expanding Clinical Indications for primaLOK SP

AUSTIN, Texas--(BUSINESS WIRE)--Wenzel Spine, Inc., a medical technology company specializing in the development of a minimally invasive surgical technology and diagnostic platform for the treatment of spinal disorders, is pleased to announce the recent FDA clearance for their primaLOK SP System. This achievement marks a significant advancement in spinal fusion technology, offering surgeons and patients a highly effective and reliable solution for spinal stabilization. The primaLOK SP System co...
Back to Newsroom